Bavarian Nordic's VIMKUNYA Chikungunya Vaccine Receives First Swiss Approval from Swissmedic

Key Takeaways

• VIMKUNYA becomes the first chikungunya vaccine approved in Switzerland by Swissmedic for patients aged 12 and above
• The single-dose virus-like particle (VLP) vaccine provides active immunization against chikungunya virus disease
• This approval expands Bavarian Nordic’s European market presence for their breakthrough chikungunya prevention solution

---

Bavarian Nordic Achieves Swiss Regulatory Milestone

Bavarian Nordic A/S (OMX: BAVA) announced on April 16, 2026, that Switzerland’s regulatory authority Swissmedic has granted approval for VIMKUNYA® (recombinant, adsorbed), marking a significant milestone as the country’s first approved chikungunya vaccine.

About VIMKUNYA Vaccine

VIMKUNYA is a virus-like particle (VLP) vaccine designed for active immunization against chikungunya virus in individuals aged 12 years and older. The single-dose formulation represents a major advancement in chikungunya prevention, offering convenient administration compared to multi-dose vaccine regimens.

Market Impact and Clinical Significance

Chikungunya virus poses a growing public health concern, particularly for travelers to endemic regions in Africa, Asia, and the Americas. The virus causes debilitating fever, joint pain, and muscle aches, with symptoms potentially lasting months or years.

This Swiss approval follows previous regulatory successes for VIMKUNYA in other markets, strengthening Bavarian Nordic’s position in the travel medicine and infectious disease prevention sectors. The company’s vaccine portfolio expansion aligns with increasing global demand for protection against emerging infectious diseases.

Regulatory Pathway and Development

Swissmedic’s approval followed comprehensive review of Bavarian Nordic’s regulatory dossier, including clinical trial data demonstrating VIMKUNYA’s safety and efficacy profile. The approval process reflects Switzerland’s rigorous standards for vaccine authorization while recognizing the urgent need for chikungunya prevention tools.

Commercial Implications

For Bavarian Nordic, this approval represents continued momentum in building a diversified vaccine portfolio beyond their established smallpox and mpox vaccines. The Swiss market provides access to a sophisticated healthcare system with strong travel medicine infrastructure, potentially driving uptake among at-risk populations.

The single-dose convenience factor may prove particularly attractive to healthcare providers and patients compared to traditional multi-visit vaccination schedules, potentially improving compliance rates and public health outcomes.

---

Frequently Asked Questions

What does this approval mean for patients in Switzerland?

Swiss patients aged 12 and older now have access to the first approved chikungunya vaccine, providing protection against a debilitating mosquito-borne disease, particularly important for travelers to endemic regions.

When will VIMKUNYA be available in Swiss pharmacies and clinics?

While Swissmedic has granted approval, Bavarian Nordic has not yet announced the commercial launch timeline. Availability will depend on manufacturing, distribution agreements, and pricing negotiations with Swiss health authorities.

How does VIMKUNYA compare to other chikungunya prevention methods?

VIMKUNYA is the first approved chikungunya vaccine in Switzerland, offering active immunization with a single dose. Previously, prevention relied solely on mosquito bite avoidance measures like repellents and protective clothing.